Please assess the completion status of the following clinical trial:

Trial Title: The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. Patient with metastatic breast cancer HER2 + (IHC+++ and/or HER2 amplification in ISH according to ASCO recommendations), ERα neg (0% in IHC) and Progesterone Receptor neg (0% in IHC).~3. Patient eligible according to the investigator for a treatment with trastuzumab + pertuzumab + taxane in the metastatic first line.~4. Available biopsy of a tumor lesion (archived material) or biopsiable tumor lesion for study (primitive tumor or metastasis other than bone).~5. OMS ≤ 2.~6. For non-menopausal patients, use of an effective contraceptive method at entry into the study and for the duration of the study.~7. Patient affiliated to a Social Health Insurance in France.~8. Patient must provide written informed consent prior to any study specific procedures.~Exclusion Criteria:~1. Any previous treatment for metastatic disease.~2. Prior adjuvant treatment with anti-HER2 antibodies taken within 6 months.~3. Patient with isolated hepatic metastasis.~4. Patient with hemostasis disorders.~5. Unbalanced Diabetes.~6. Patient with usual formal contraindication to PET/TDM Imaging.~7. Patient who has already started trastuzumab + pertuzumab + taxane treatment.~8. Pregnant or breastfeeding women.~9. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure.~10. Patient protected by law.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with metastatic breast cancer (Type: OTHER): Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.

Based on this trial design, predict the completion outcome and termination type (if applicable).